

May 23, 2018



## SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention

JERSEY CITY, N.J., May 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International Conference at the Boston Convention and Exhibition Center on Wednesday, June 6, 2018 from 4:15 – 5:15 p.m. ET. The panel, titled "[Fueling Antifungus Among Us: The Cost to Keep Up](#)," will explore strategies to fund the development of antifungal treatments. Panel participants will include representatives from the private and public equity communities and fellow antifungal treatment developers.

### About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative anti-infective therapies. The [SCYNEXIS team](#) has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, [SCY-078](#), is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit [www.scynexis.com](http://www.scynexis.com).

### CONTACT:

#### Media Relations

George E. MacDougall  
MacDougall Biomedical Communications  
Tel: 781-235-3093  
[george@macbiocom.com](mailto:george@macbiocom.com)

#### Investor Relations

Susan Kim  
Argot Partners  
Tel: 212-203-4433  
[susan@argotpartners.com](mailto:susan@argotpartners.com)

View original content: <http://www.prnewswire.com/news-releases/scynexis-to-participate-in-a-panel-at-the-2018-bio-international-convention-300652176.html>

SOURCE SCYNEXIS, Inc.